The research team is now monitoring 12 more participants who received higher doses of 150,000 and 250,000 cells. If no safety ...

In a study published in Cell Stem Cell, scientists tested retinal pigment epithelial stem cells in a phase 1/2a clinical trial. The cells were obtained from adult postmortem eye tissue. These ...

A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show ...

The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...

University of Minnesota Medical School researchers have shown that reducing chronic inflammation can significantly protect against age-related macular degeneration (AMD)-like pathology in preclinical ...

The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals ...

Coave Therapeutics has announced its lead gene therapy program, CoTx-101, for the treatment of retinal vascular diseases, ...

Introduction Age-related macular degeneration (AMD) is a prevalent eye disease among middle-aged and older adults. AMD leaves the patient with irreversible deteriorating vision, which profoundly ...

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

Optometrist Amy Green discussed the importance of OCT in identifying AMD cases during the AOP’s Locum Clinical Skills ...

In this video, David A. Eichenbaum, MD, FASRS, discusses late-stage wet age-related macular degeneration assets presented at the American Academy of Ophthalmology meeting.Eichenbaum noted that ...

Valitor, a biotechnology company engineering a new generation of ophthalmic medicines, today announced its chief executive officer, Gregory D. Kunst, will present preclinical data highlighting the ...